The QBE Insurance Group (ASX: QBE) share price is in focus after the company announced it has successfully priced US$300 million of fixed-rate subordinated notes due in 2037, strengthening its capital base under the Australian Prudential Regulation Authority's (APRA) framework.
Image source: Getty Images
What did QBE Insurance Group report?
- Issued US$300 million of Fixed Rate Resetting Subordinated Notes maturing in November 2037
- Initial fixed interest rate of 5.239% per annum, paid semi-annually until November 2032
- Eligible as Tier 2 Capital under APRA's capital adequacy standards
- Notes callable early by QBE (with APRA approval) from November 2032
- Interest rate resets in 2032 to US Treasury five-year yield plus 1.35%
What else do investors need to know?
The subordinated notes will be convertible to QBE ordinary shares in full or part if APRA determines QBE is, or would become, non-viable. This is a standard provision under APRA's capital requirements, aimed at providing an additional capital buffer in times of stress.
QBE highlighted that investors should not expect APRA's approval for early redemption of the notes, except under specific tax or regulatory circumstances. The offer is part of QBE's strategic capital management and is targeted at institutional investors rather than the general public, consistent with broader market practices for Tier 2 instruments.
What's next for QBE Insurance Group?
QBE plans to use the proceeds to support overall funding flexibility and maintain regulatory capital strength as it pursues growth and underwriting discipline across its global portfolio. Management continues to focus on sustainable returns, efficient capital use, and maintaining a strong balance sheet in dynamic insurance markets.
Looking ahead, QBE's robust capital management is expected to help it meet regulatory demands and pursue new business opportunities, while providing resilience through ongoing market cycles.
QBE Insurance Group share price snapshot
QBE Insurance shares have risen 15% over the past 12 months, outperforming the S&P/ASX 200 Index (ASX: XJO) which has risen 8% over the same period.
